Invasive Infections with Multidrug-Resistant Yeast <i>Candida auris</i>, Colombia

Morales-López, Soraya E.; Parra-Giraldo, Claudia Marcela; Ceballos-Garzón, Andrés; Martínez, Heidys P.; Rodríguez, Gerson J.; Álvarez-Moreno, Carlos; Rodríguez, José Yesid

doi:10.3201/eid2301.161497

Cited by 211 publications

(196 citation statements)

References 7 publications

Supporting

Mentioning

166

Contrasting

Unclassified

Order By: Relevance

“…After observing the unusual prevalence and the micromorphological discordance, the strains were cultured in CHROMagar Candida medium using MALDI-TOF. Pink colonies were observed in the CHROMagar Candida medium and there was subsequently molecular confirmation of C. auris in all isolates 14 . According to Chowdhary et al, growth at 40 °C may differentiate the isolates of C. auris that are mistakenly identified as C. haemulonii by VITEK, considering that the species Candida haemulonii does not grow at 40 °C.…”

Section: Identificationmentioning

confidence: 97%

“…guilliermondii, S. cerevisiae and R. glutinis and that presented high minimal inhibitory concentrations (MIC) for fluconazole (FCZ; MIC≥ 32 µg/mL), voriconazole (VCZ; MIC≥ 2 µg/mL), amphotericin B (APHB; MIC≥2 µg/mL), and echinocandins (ECHs), such as anidulafungin (ADA; ≥2 µg/mL) 9 . This new species can be erroneously identified as those mentioned above 9,14 , if identification is made through classical methods 6,9 . Gaitan et al 6 initially described isolates identified as S. cerevisiae, C. sake, C. lusitaniae, C. haemulonii, and eight inconclusive isolates, and 8 (eight) were isolated from the blood and 4 (four) from the tip of the catheter, from patients hospitalized in an ICU in a European hospital.…”

Section: Identificationmentioning

confidence: 97%

“…Infections caused by this new species of Candida are diagnosed by blood culture or culture of other body fluids. Its specific identification requires molecular laboratory methods, such as D1-D2 or Internal Transcribed Spacer (ITS) 9,12,13 , or desorption/ionization with mass spectrometry, and the Matrix-Assisted Laser Desorption Ionization -Time of Flight (MALDI-TOF), the fastest and most suitable method described in the literature for the identification of C. auris 14 , making it possible to create reference spectrum and the care to be taken when adopting this approach.…”

Section: Identificationmentioning

confidence: 99%

“…Thus, it is observed in the literature that the identification and the diagnoses of C. auris are definitely carried out by molecular methods 6,8,9,[12][13][14][15][16][17][18][19][20][21] . Routine methods (direct, culture, biochemical tests) are used only as screening for initial detection of yeast in clinical samples.…”

Section: Identificationmentioning

confidence: 99%

“…Most of the patients had central venous catheter, urinary catheter, and mechanical ventilation. Some had risk factors for candidemia: red blood cell transfusion, parenteral nutrition, abdominal surgery, hemodialysis, diabetes, pancreatitis, cancer, and HIV infection 14 . In India, the highest incidence of C. auris infection has occurred in public hospitals.…”

Section: Epidemiologymentioning

confidence: 99%

See 4 more Smart Citations

Candida Auris: Emergence and Epidemiology of a Highly Pathogenic Yeast

Santos¹,

Lana²,

Mezzari³

2017

Clin. Biomed. Res.

View full text Add to dashboard Cite

Candida auris is a multidrug-resistant emerging yeast, which was responsible for healthcare-associated infection outbreaks, and was cataloged as a new species in 2009, after being isolated from a patient's ear canal secretion in Japan. Since the notification of this first occurrence, numerous cases have been reported throughout the world, including Brazil. C. auris affects mainly inpatients, patients in intensive care units, exposed to broad-spectrum antifungal medications and who make use of vascular catheters. Currently, this yeast is one of the main responsible for invasive infections in hospitals and has been cause of concern by authorities and organs due to its rapid dissemination and difficult treatment caused by its low susceptibility to antifungal agents traditionally used in clinical practice. As a contributor to the severity of infections associated with C. auris, the transmission mechanism is still unknown, which implies in a lack of control of the microorganism and high mortality rates. Thus, this literature review presents relevant information in order to alert the importance of C. auris as an etiological agent of systemic infections, as well as its epidemiology and the real challenges of the treatment.

show abstract

Section: Identificationmentioning

confidence: 97%

Section: Identificationmentioning

confidence: 97%

Section: Identificationmentioning

confidence: 99%

Section: Identificationmentioning

confidence: 99%

Section: Epidemiologymentioning

confidence: 99%

See 3 more Smart Citations

Candida Auris: Emergence and Epidemiology of a Highly Pathogenic Yeast

Santos¹,

Lana²,

Mezzari³

2017

Clin. Biomed. Res.

View full text Add to dashboard Cite

show abstract

A Cerberus‐Inspired Anti‐Infective Multicomponent Gatekeeper Hydrogel against Infections with the Emerging “Superbug” Yeast Candida auris

Kubiczek

Flaig

Raber

et al. 2020

Macromolecular Bioscience

View full text Add to dashboard Cite

The pathogenic yeast Candida auris has received increasing attention due to its ability to cause fatal infections, its resistance toward important fungicides, and its ability to persist on surfaces including medical devices in hospitals. To brace health care systems for this considerable risk, alternative therapeutic approaches such as antifungal peptides are urgently needed. In clinical wound care, a significant focus has been directed toward novel surgical (wound) dressings as first defense lines against C. auris. Inspired by Cerberus the Greek mythological “hound of Hades” that prevents the living from entering and the dead from leaving hell, the preparation of a gatekeeper hybrid hydrogel is reported featuring lectin‐mediated high‐affinity immobilization of C. auris cells from a collagen gel as a model substratum in combination with a release of an antifungal peptide drug to kill the trapped cells. The vision is an efficient and safe two‐layer medical composite hydrogel for the treatment of severe wound infections that typically occur in hospitals. Providing this new armament to the repertoire of possibilities for wound care in critical (intensive care) units may open new routes to shield and defend patients from infections and clinical facilities from spreading and invasion of C. auris and probably other fungal pathogens.

show abstract

Candida auris: A systematic review and meta‐analysis of current updates on an emerging multidrug‐resistant pathogen

2018

View full text Add to dashboard Cite

From 2009, Candida auris has emerged as a multidrug‐resistant ascomycete yeast pathogen with the capacity for easy transmission between patients and hospitals, as well as persistence on environmental surfaces. Its association with high mortalities, breakthrough and persistent candidaemia, inconsistencies in susceptibility testing results, misidentification by available commercial identification systems and treatment failure, complicates its management and detection. Within the last nine years, C. auris has been increasingly reported from far‐Eastern Asia, the Middle East, Africa, Europe, South and North America with substantial fatalities and misidentification. Herein, I provide a systematic and thorough review of this emerging pathogen. Meta‐analysis showed that at least 742 C. auris isolates have been reported in 16 countries, with most of these being from India (≥243), USA (≥232) and UK (≥103) (p‐value = .0355) within 2013–2017. Most isolates were from males (64.76%) (p‐value = .0329) and blood (67.48%) (p‐value < .0001), with substantial crude mortality (29.75%) (p‐value = .0488). Affected patients presented with other comorbidities: diabetes (≥52), sepsis (≥48), lung diseases (≥39), kidney diseases (≥32) etc. (p‐value < .0001). Resistance to fluconazole (44.29%), amphotericin B (15.46%), voriconazole (12.67%), caspofungin (3.48%) etc. were common (p‐value = .0059). Commonly used diagnostic tools included PCR (30.38%), Bruker MALDI‐TOF MS (14.00%), Vitek 2 YST ID (11.93%), AFLP (11.55%) and WGS (10.04%) (p‐value = .002). Multidrug resistance, high attributable mortality and persistence are associated with C. auris infections. Two novel drugs, SCY‐078 and VT‐1598, are currently in the pipeline. Contact precautions, strict infection control, periodic surveillance and cleaning with chlorine‐based detergents, efficient, faster and cheaper detection tools are necessary for prevention, containment and early diagnosis of C. auris infections.

show abstract

Invasive Infections with Multidrug-Resistant Yeast Candida auris, Colombia

Cited by 211 publications

References 7 publications

Candida Auris: Emergence and Epidemiology of a Highly Pathogenic Yeast

Candida Auris: Emergence and Epidemiology of a Highly Pathogenic Yeast

A Cerberus‐Inspired Anti‐Infective Multicomponent Gatekeeper Hydrogel against Infections with the Emerging “Superbug” Yeast Candida auris

Candida auris: A systematic review and meta‐analysis of current updates on an emerging multidrug‐resistant pathogen

Contact Info

Product

Resources

About